Abstract:During the transplant process, the graft is exposed to numerous events, which may enhance its immunogenicity. In particular, factors related to brain death, such as hemodynamic instability and systemic release of cytokines, cold preservation on harvesting, and reperfusion injury, are known to accumulate in harm, conveying a proinflammatory state to the graft before transplant. Alloimmune reactivity is initiated when the host immune system detects non-self-antigens in the context of "danger signals." Eliminating these danger signals by modifying the graft before transplant has the potential to attenuate the alloimmune response. The molecules, which mediate danger signals, have not yet been fully identified. Free oxygen radicals and interferon-gamma are important candidates. One of the most important protective mechanisms against oxidative stress is the heme oxygenase 1 system. Up-regulation of heme oxygenase 1 in grafts has been shown to prevent ischemia-reperfusion damage and improve long-term graft survival in various transplant models. The benefit of blocking the action of interferon-gamma in kidney transplants is less clear because the compound plays such a complex and pivotal role in the immune response, and experimental data with interferon-gamma receptor knockout mice are conflicting. It has recently become clear that catecholamines are important graft-modifying agents. Dopamine is capable of stimulating the induction of protective enzymes like heme oxygenase-1 (HO-1) rendering the organ more resistant to the insult of ischemia/reperfusion and inflammation. Retrospective clinical data suggest that treatment of brain-dead organ donors with catecholamines is associated with less rejection and a better long-term graft survival of kidneys transplanted from these donors. Catecholamines can also modulate cytokine production and prevent cold-induced damage. Other substances, such as proteoglycans and phosphatidylethanolamine-bound hyaluronic acid, may interfere with the actions of interferon-gamma. Further studies of these compounds in experimental animal models and in prospective randomized clinical trials will help establish their efficacy in donor pretreatment. It is important to underscore that donor pretreatment will have great advantages for the recipient because an improved long-term graft survival could thus be achieved cost-efficiently and without great effort or side effects.

Current Antioxidant Treatments in Organ Transplantation

Role of Reactive Oxygen Species in Mediating Hepatic Ischemia-Reperfusion Injury and Its Therapeutic Applications in Liver Transplantation

Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants.

The Role of Ischemia/Reperfusion Injury in Early Hepatic Allograft Dysfunction

New therapeutic concepts against ischemia-reperfusion injury in organ transplantation

Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants

Ascorbic acid in solid organ transplantation: A literature review

Modification of Preservative Fluids with Antioxidants in Terms of Their Efficacy in Liver Protection before Transplantation

Novel, Innovative Models to Study Ischemia/Reperfusion-Related Redox Damage in Organ Transplantation

Lack of Long-Term Protective Effect of Antioxidant/Anti-Inflammatory Therapy in Transplant-Induced Ischemia/Reperfusion Injury

Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation

Preconditioning strategies to limit graft immunogenicity and cold ischemic organ injury

Ischemia-free organ transplantation - a review

Liver Protection Strategies in Liver Transplantation

Assessment of Oxidative Stress Markers in Hypothermic Preservation of Transplanted Kidneys

Cellular and molecular mechanisms of cell damage and cell death in ischemia–reperfusion injury in organ transplantation

Enzyme Therapeutic for Ischemia and Reperfusion Injury in Organ Transplantation

Optimized donor management and organ preservation before kidney transplantation

Can ischemic preconditioning alone really protect organs from ischemia reperfusion injury in transplantation

Restoring Mitochondrial Function While Avoiding Redox Stress: The Key to Preventing Ischemia/Reperfusion Injury in Machine Perfused Liver Grafts?

CD4+CD25+FOXP3+ regulatory T cells: a potential "armor" to shield "transplanted allografts" in the war against ischemia reperfusion injury